Clinical Trial Update: P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 study of SB-681323, a P38 MAP kinase inhibitor, in neuropathic pain has completed enrollment. Availability of efficacy or safety results is not provided…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain

Drugs mentioned

• SB-681323

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pain, Neuropathic | Phase 2 | Status: COMPLETED